Therapeutic effect of an aromatic retinoic acid analog on rats with bladder carcinoma upon administration alone or in combination with mitomycin C.
An aromatic retinoic acid analog (Ro 10-9359) was given orally in combination with intraperitoneal administration of mitomycin C (MMC), in an attempt to reduce the toxicity and enhance the therapeutic effect. Male ACI/N rats were inoculated subcutaneously with BC50-TC cells, an established bladder carcinoma cell line of ACI/N rats. The chemotherapy was initiated at 16 days after the inoculation and continued for 4 weeks thereafter. Tumor growth was significantly inhibited in the rats given 100 mg/kg/week Ro 10-9359 or 0.3 mg/kg/twice a week MMC. Neither additive nor synergistic effect was apparent when these two drugs were given simultaneously. No effect was seen when 0.1 mg/kg/twice a week MMC was given alone or in combination with Ro 10-9359. MMC may suppress Ro 10-9359 activity directly or indirectly by affecting the responding cells. Therefore care should be taken when prescribing retinoids with MMC or possibly with other cytotoxic agents.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000032:analysis; D004359:Drug Therapy, Combination; D005050:Etretinate / Q000627:therapeutic use*; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats; D011912:Rats, Inbred ACI; D018168:Receptors, Retinoic Acid; D014212:Tretinoin / Q000031:analogs & derivatives*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014801:Vitamin A / Q000627:therapeutic use
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D008937:Mitomycins; D018168:Receptors, Retinoic Acid; D014801:Vitamin A; D016685:Mitomycin; D014212:Tretinoin; D005050:Etretinate